Improved survival with radiotherapy in hepatocellular carcinoma with major vascular invasion: A propensity-matched analysis of Surveillance, Epidemiology, and End Results database

被引:17
作者
Lin, Qiuyan [1 ]
Huang, Xiaoquan [2 ]
Zhong, Canmei [1 ]
Luo, Tiancheng [2 ]
Zeng, Xiaoqing [2 ]
Chen, Shiyao [2 ]
机构
[1] Fujian Med Univ, Union Hosp, Dept Gastroenterol, Fuzhou, Fujian, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Gastroenterol, Shanghai, Peoples R China
关键词
hepatocellular carcinoma; major vascular invasion; propensity score-match; radiotherapy; Surveillance; Epidemiology; and End Results; LIVER RESECTION; PROGNOSTIC-FACTOR; NATURAL-HISTORY; TUMOR; CHEMOEMBOLIZATION; SORAFENIB; MANAGEMENT; FEATURES; THERAPY;
D O I
10.1002/cam4.1937
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives Hepatocellular carcinoma (HCC) associated with major vascular invasion is an advanced stage disease with an extremely poor prognosis and low survival rate. Our study evaluated the survival benefit of radiotherapy (RT) in HCC patients with major vascular invasion through Surveillance, Epidemiology, and End Results database. Methods We analyzed 3181 HCC patients with major vascular invasion cases diagnosed from 2004 to 2013. Patients (N = 308) who underwent RT and patients (N = 2873) who did not receive RT were compared. We successfully analyzed patients using propensity score matching (PSM). Kaplan-Meier and Cox-regression analyses were applied to assess prognosis. Results The median survival time in radiation-treated group was longer compared to the control group (7 months vs 3 months; P < 0.001) in the overall sample and 3 months longer compared to the control group (7 months vs 4 months; P < 0.001) in a PSM cohort. Cox-regression analyses showed that radiation-treated patients in propensity-matched sample had a significantly lower risk of mortality (HR: 0.625, 95% CI: 0.522-0.749, P < 0.001) compared with untreated patients. The radiation-treated groups had better survival rate than untreated group. Subgroup analysis revealed that the survival time of patients in radiation-treated group was significantly longer than that in the untreated group (P P = 0.026, respectively). The subgroup analysis also revealed that RT provides a survival benefit regardless of race, marital status, and tumor size after PSM. Conclusions Radiotherapy provides improves survival in HCC patients with major vascular invasion, especially for tumor(s) confined to one lobe and not on surface of liver.
引用
收藏
页码:515 / 526
页数:12
相关论文
共 39 条
[1]   Phase II study of sorafenib in patients with advanced hepatocellular carcinoma [J].
Abou-Alfa, Ghassan K. ;
Schwartz, Lawrence ;
Ricci, Sergio ;
Amadori, Dino ;
Santoro, Armando ;
Figer, Arie ;
De Greve, Jacques ;
Douillard, Jean-Yves ;
Lathia, Chetan ;
Schwartz, Brian ;
Taylor, Ian ;
Moscovici, Marius ;
Saltz, Leonard B. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) :4293-4300
[2]  
[Anonymous], JPN J RADIOL
[3]  
[Anonymous], HEPATOLOGY
[4]  
[Anonymous], SEER PROGR 2018
[5]   Radiation induced liver disease: A clinical update [J].
Benson, R. ;
Madan, R. ;
Kilambi, R. ;
Chander, S. .
JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2016, 28 (01) :7-11
[6]   Radiation Segmentectomy versus Selective Chemoembolization in the Treatment of Early-Stage Hepatocellular Carcinoma [J].
Biederman, Derek M. ;
Titano, Joseph J. ;
Korff, Ricki A. ;
Fischman, Aaron M. ;
Patel, Rahul S. ;
Nowakowski, Francis S. ;
Lookstein, Robert A. ;
Kim, Edward .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2018, 29 (01) :30-37
[7]   Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial [J].
Bruix, Jordi ;
Raoul, Jean-Luc ;
Sherman, Morris ;
Mazzaferro, Vincenzo ;
Bolondi, Luigi ;
Craxi, Antonio ;
Galle, Peter R. ;
Santoro, Armando ;
Beaugrand, Michel ;
Sangiovanni, Angelo ;
Porta, Camillo ;
Gerken, Guido ;
Marrero, Jorge A. ;
Nadel, Andrea ;
Shan, Michael ;
Moscovici, Marius ;
Voliotis, Dimitris ;
Llovet, Josep M. .
JOURNAL OF HEPATOLOGY, 2012, 57 (04) :821-829
[8]   Leukocyte Cell-Derived Chemotaxin 2 Antagonizes MET Receptor Activation to Suppress Hepatocellular Carcinoma Vascular Invasion by Protein Tyrosine Phosphatase 1B Recruitment [J].
Chen, Chi-Kuan ;
Yang, Ching-Yao ;
Hua, Kuo-Tai ;
Ho, Ming-Chih ;
Johansson, Gunnar ;
Jeng, Yung-Ming ;
Chen, Chiung-Nien ;
Chen, Min-Wei ;
Lee, Wei-Jiunn ;
Su, Jen-Liang ;
Lai, Tsung-Ching ;
Chou, Chi-Chi ;
Ho, Bing-Ching ;
Chang, Chuan-Fa ;
Lee, Po-Huang ;
Chang, King-Jen ;
Hsiao, Michael ;
Lin, Ming-Tsan ;
Kuo, Min-Liang .
HEPATOLOGY, 2014, 59 (03) :974-985
[9]   Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong [J].
Cheung, T. -K. ;
Lai, C. -L. ;
Wong, B. C. -Y. ;
Fung, J. ;
Yuen, M. -F. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (04) :573-583
[10]   Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy [J].
Choi, Yunseon ;
Kim, Jun Won ;
Cha, Hyejung ;
Han, Kwang Hyub ;
Seong, Jinsil .
JOURNAL OF RADIATION RESEARCH, 2014, 55 (01) :113-120